UA97143C2 - КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК - Google Patents

КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК

Info

Publication number
UA97143C2
UA97143C2 UAA200910735A UAA200910735A UA97143C2 UA 97143 C2 UA97143 C2 UA 97143C2 UA A200910735 A UAA200910735 A UA A200910735A UA A200910735 A UAA200910735 A UA A200910735A UA 97143 C2 UA97143 C2 UA 97143C2
Authority
UA
Ukraine
Prior art keywords
nucleic acid
acid delivery
prompt
delivery carrier
carrier composition
Prior art date
Application number
UAA200910735A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хірофумі Такеуті
Ясуюкі Хіра
Кодзі Накано
Хідеказу Тойобуку
Original Assignee
Хірофумі Такеуті
Оцука Фармасьютікал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хірофумі Такеуті, Оцука Фармасьютікал Ко., Лтд. filed Critical Хірофумі Такеуті
Publication of UA97143C2 publication Critical patent/UA97143C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение касается композиции носителя для доставки миРНК, который содержит композицию носителя и миРНК, где носитель для доставки нуклеиновой кислоты получают при использовании (А) диацилфосфатидилхолина, (В) по меньшей мере одного компонента, выбранного из группы, которая состоит из холестерина и его производных, и (С) алифатически первичного амина.
UAA200910735A 2007-03-26 2008-03-26 КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК UA97143C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007079944 2007-03-26
PCT/JP2008/055730 WO2008117828A1 (ja) 2007-03-26 2008-03-26 即効型核酸送達用キャリアー組成物

Publications (1)

Publication Number Publication Date
UA97143C2 true UA97143C2 (ru) 2012-01-10

Family

ID=39788561

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910735A UA97143C2 (ru) 2007-03-26 2008-03-26 КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК

Country Status (26)

Country Link
US (1) US9315828B2 (ru)
EP (1) EP2140870B1 (ru)
JP (1) JP5349293B2 (ru)
KR (1) KR101459391B1 (ru)
CN (1) CN101646443B (ru)
AR (1) AR065847A1 (ru)
AU (1) AU2008230379B2 (ru)
BR (1) BRPI0809634A2 (ru)
CA (1) CA2682490A1 (ru)
CO (1) CO6241127A2 (ru)
DK (1) DK2140870T3 (ru)
ES (1) ES2542864T3 (ru)
HR (1) HRP20150927T1 (ru)
HU (1) HUE027053T2 (ru)
IL (1) IL201116A0 (ru)
MX (1) MX2009010336A (ru)
MY (1) MY151450A (ru)
NZ (1) NZ579804A (ru)
PL (1) PL2140870T3 (ru)
PT (1) PT2140870E (ru)
RU (1) RU2476229C2 (ru)
SI (1) SI2140870T1 (ru)
TW (1) TWI428135B (ru)
UA (1) UA97143C2 (ru)
WO (1) WO2008117828A1 (ru)
ZA (1) ZA200906576B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110128325A (ko) * 2009-03-04 2011-11-29 히로후미 다케우치 핵산 복합체 및 핵산 송달용 조성물
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
CA2809858C (en) 2010-09-20 2019-11-12 Sirna Therapeutics, Inc. Novel low molecular weight cationic lipids for oligonucleotide delivery
JP6029131B2 (ja) * 2011-12-28 2016-11-24 国立研究開発法人国立循環器病研究センター 核酸導入剤、核酸導入方法及び細胞
WO2017187426A1 (en) 2016-04-29 2017-11-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
AU2017378427A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750910A4 (en) * 1994-03-11 1997-07-09 Yoshitomi Pharmaceutical PREPARATION OF LIPOSOMES
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
US6835395B1 (en) * 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
JPH10313872A (ja) 1997-05-21 1998-12-02 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス剤
WO1999013816A2 (en) 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6740335B1 (en) * 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
NZ512244A (en) * 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
AU2001287820A1 (en) * 2000-09-08 2002-03-22 Aventis Pasteur Use of lipopeptides for immunotherapy of hiv-positive subjects
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004045582A1 (en) * 2002-11-21 2004-06-03 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
EP1640360A4 (en) * 2003-06-27 2007-06-20 Sumitomo Chemical Co AMIDE AND METHOD FOR COMBATING PLANT DISEASES THEREFOR
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
DE602004030923D1 (de) * 2003-09-17 2011-02-17 Rodos Biotarget Gmbh Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen
EP1759691A1 (en) 2003-11-20 2007-03-07 Delex Therapeutics Inc. Stable liposome compositions
AT500143A1 (de) 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2005336081A (ja) 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
EP1773857A4 (en) * 2004-07-02 2009-05-13 Protiva Biotherapeutics Inc THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF
CA2587411A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
WO2006138380A2 (en) * 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
UA97559C2 (ru) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеиновой кислоты и композиция для доставки нуклеиновой кислоты

Also Published As

Publication number Publication date
JPWO2008117828A1 (ja) 2010-07-15
CN101646443A (zh) 2010-02-10
MY151450A (en) 2014-05-30
AU2008230379A1 (en) 2008-10-02
PL2140870T3 (pl) 2015-11-30
AU2008230379B2 (en) 2012-12-06
WO2008117828A1 (ja) 2008-10-02
CN101646443B (zh) 2015-01-14
MX2009010336A (es) 2009-10-16
BRPI0809634A2 (pt) 2014-09-23
CA2682490A1 (en) 2008-10-02
SI2140870T1 (sl) 2015-10-30
US9315828B2 (en) 2016-04-19
HK1139041A1 (en) 2010-09-10
IL201116A0 (en) 2010-05-17
ES2542864T3 (es) 2015-08-12
PT2140870E (pt) 2015-09-15
ZA200906576B (en) 2010-11-24
HUE027053T2 (en) 2016-08-29
EP2140870A4 (en) 2011-09-07
HRP20150927T1 (hr) 2015-10-09
KR20090130056A (ko) 2009-12-17
US20100063131A1 (en) 2010-03-11
KR101459391B1 (ko) 2014-11-07
AR065847A1 (es) 2009-07-08
CO6241127A2 (es) 2011-01-20
RU2476229C2 (ru) 2013-02-27
TWI428135B (zh) 2014-03-01
RU2009139246A (ru) 2011-05-10
NZ579804A (en) 2012-05-25
TW200902035A (en) 2009-01-16
DK2140870T3 (en) 2015-07-20
EP2140870A1 (en) 2010-01-06
JP5349293B2 (ja) 2013-11-20
EP2140870B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
FR2925317B1 (fr) Composition comprenant une alcanolamine, un acide amine et un ester de sorbitan polyoxethylene.
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
PH12017501298A1 (en) Pesticidal compositions and processes related thereto
WO2011113798A3 (en) Inhibitors of semicarabazide - sensitive amine oxidase
WO2012116246A3 (en) Pesticidal compostions and processes related thereto
PH12013502686A1 (en) Pesticidal compositions and processes related thereto
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
MX343625B (es) Composiciones plagicidas.
MX336823B (es) Revestimientos basados en solvente, curados al ambiente para superficies escribibles-borrables.
UA97143C2 (ru) КОМПОЗИЦИЯ НОСИТЕЛЯ ДЛЯ СВОЕВРЕМЕННОЙ ДОСТАВКИ миРНК
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
MX2010003323A (es) Composiciones de poliplex de quitosana-acido nucleico de alta concentracion.
ECSP11010812A (es) Complejo de mineral-aminoácido polisacárido
WO2010115822A3 (en) Fixing means
GEP20135800B (en) Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
TN2009000536A1 (en) Novel herbicides
BRPI0620229A8 (pt) formulação
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
TW200745270A (en) Acid dyes
WO2009138352A3 (en) Fibre-reactive dystuffs containing a trifluoromethyl group
TW200708571A (en) Acid dye composition
UA39081U (ru) Препарат для коррекции стресс-индуцированной недостаточности "янтарин"
UA39083U (ru) Продукт (препарат) для снятия признаков интоксикации любой этиологии "янтарин-детокс"